SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended		3 Months Ended	6 Months Ended		12 Months Ended
	Aug. 15, 2025	Jan. 16, 2025	Jan. 14, 2025	Sep. 23, 2024	Aug. 15, 2025	Sep. 30, 2024	Jun. 30, 2025	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024	May 31, 2025	Jul. 31, 2023	May 10, 2023
Subsidiary, Sale of Stock [Line Items]
Shares authorized													120,000,000
Common stock, shares issued							100,000,000	100,000,000		100,000,000			100,000,000
Common stock, par value							$ 0.001	$ 0.001		$ 0.001			$ 0.001
Preferred stock, shares authorized							20,000,000	20,000,000		20,000,000			20,000,000
Preferred stock par value							$ 0.001	$ 0.001		$ 0.001			$ 0.001
Common stock, shares issued							17,743,765	17,743,765		13,736,597
Common stock, shares outstanding							17,743,765	17,743,765		13,736,597
Preferred stock, shares outstanding							0	0		0
Warrants exercisable description			will be exercisable six months from issuance and will expire five and a half years from the issuance date.
Net proceeds								$ 223
Common stock issued for cash upon exercise of the company's equity line of credit							$ 210	210
Fair value of shares							77	$ 153
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares vested								78,521
Granted shares								20,120
Stock compensation-related expense for fair value vesting of restricted common stock								$ 153
Fair value of unamortized compensation							$ 192	192
Restricted Stock Units (RSUs) [Member] \| Three Independent Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Fair value of shares								$ 50
Number of shares vested								0		0
Restricted Stock Units (RSUs) [Member] \| Director [Member]
Subsidiary, Sale of Stock [Line Items]
Fair value of shares								$ 31		$ 74
Granted shares								20,120		30,000
Restricted Stock Units (RSUs) [Member] \| Strategic Advisory Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued				50,000
Fair value of shares				$ 100
Number of shares vested								50,000		0
Restricted Stock Units (RSUs) [Member] \| Four Officers Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued						92,000
Fair value of shares						$ 226
Number of shares vested								28,521		0
2023 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for future issuance												1,650,000
Shares available for grant							1,457,880	1,457,880		1,457,880
Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash upon exercise of the company's equity line of credit	$ 3,693
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase stock											35,700
Exercisable price per share							$ 0.46	$ 0.46			$ 0.40
Warrant shares outstanding, intrinsic value							$ 4	$ 4
Pre-Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Exercisable price per share			$ 0.001
Warrants exercised								2,500,000
Common Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercisable price per share			$ 1.40
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase stock							35,700	35,700
Warrants exercised							490,000
Common stock issued for cash upon exercise of the company's equity line of credit, shares							510,000	510,000
Net proceeds							$ 210	$ 210
Common stock issued for cash upon exercise of the company's equity line of credit							1	1
Fair value of shares
Common Stock [Member] \| Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash upon exercise of the company's equity line of credit, shares					3,000,000
Common stock issued for cash upon exercise of the company's equity line of credit					$ 3,693
Security Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase price of pre-funded unit		$ 3,500
Shares issued, price per share		$ 1.40
Net proceeds received from financing		$ 3,058
Security Purchase Agreement [Member] \| Pre-Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction			2,500,000
Exercisable price per share			$ 0.001
Warrants to purchase stock			3,750,000
Security Purchase Agreement [Member] \| Pre-Funded Warrant [Member] \| Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase stock		2,500,000					2,500,000	2,500,000
Exercisable price per share		$ 0.001
Security Purchase Agreement [Member] \| Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Exercisable price per share			$ 1.399
Security Purchase Agreement [Member] \| Warrant [Member] \| Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase stock							3,750,000	3,750,000
Exercisable price per share							$ 1.40	$ 1.40
Warrants exercisable description								The warrant will be exercisable six months from the date of issuance (July 2025) and will expire five years from the issuance date.
Security Purchase Agreement [Member] \| Warrant [Member] \| Underwriters [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase stock		175,000
Exercisable price per share		$ 1.40
Warrants exercisable description		The warrant vested upon grant and expire five years from the date of grant.

Kairos Pharma, LTD. 10-Q